SEC Tracker
Get the app

Integra Lifesciences Holdings IART

Integra Lifesciences Holdings Q1 FY24: revenue $368.9M; diluted EPS −$0.04

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Integra Lifesciences Holdings reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$368.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$3.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.04No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$591.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$15.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Integra Lifesciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. NovoCure NVCR public float $995M, Jun 30, 2025
  2. SI-BONE SIBN public float $800M, Jun 30, 2025
  3. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
  4. Mimedx Group MDXG public float $719M, Jun 30, 2025
  5. Beta Bionics BBNX public float $632M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.